Abdelmassih Youssef, Mauget-Faÿsse Martine, Seners Pierre, Milea Dan, Hallali Gabriel, Guillaume Jessica, Lecler Augustin, Vignal Catherine, Le Mer Yannick, Paques Michel, Bonnin Sophie, Obadia Michael
Department of Ophthalmology, Rothschild Foundation Hospital, Paris, France.
Department of Neurology and Stroke Center, Rothschild Foundation Hospital, Paris, France.
Int J Stroke. 2025 Mar;20(3):338-346. doi: 10.1177/17474930241306692. Epub 2024 Dec 24.
The visual outcome after central retinal artery occlusion (CRAO) is poor, but its relationship with early reperfusion (ER) is poorly known. We evaluated the incidence of ER in acute CRAO or branch retinal artery occlusion (BRAO), and its association with clinical outcome.
In this prospective observational multicenter study, we included patients with acute CRAO or macula-involving BRAO presenting within 24 hours from symptom onset. ER was evaluated within 24 hours after the initial clinical evaluation using indocyanine green angiography (ICGA). The primary outcome was the best-corrected visual acuity (BCVA) at 1 month.
In all, 70 patients were enrolled, of whom 63 (90%) had CRAO. Median age was 71 years (interquartile range: 67-77), 63% were male, median time from symptom onset to presentation was 5.3 hours (interquartile range: 3.1-15.1), and 17% received intravenous fibrinolysis. ER was identified in 34 patients (49%), of whom 21 (30%) achieved complete reperfusion (100% filling of the 55° ICGA field). Patients with ER were less likely to have hypertension and diabetes mellitus ( < 0.001 and = 0.046, respectively). At the 1-month follow-up, BCVA was significantly better in ER patients (median BCVA 1.3 logMAR vs 1.7 logMAR, = 0.001), with greater benefit with complete reperfusion ( for trend < 0.001). ER was also associated with improved visual field and quality of life at the 1-month follow-up (both < 0.05).
ER occurred in almost 50% of the patients and was associated with improved visual outcomes and quality of life. Therapies that increase ER in CRAO will likely improve clinical outcomes.
This study was registered on ClinicalTrials.gov (identifier ); https://classic.clinicaltrials.gov/ct2/show/NCT03049514.
视网膜中央动脉阻塞(CRAO)后的视力预后较差,但其与早期再灌注(ER)的关系尚不清楚。我们评估了急性CRAO或视网膜分支动脉阻塞(BRAO)中ER的发生率及其与临床结局的关联。
在这项前瞻性观察性多中心研究中,我们纳入了症状发作后24小时内就诊的急性CRAO或累及黄斑的BRAO患者。在初次临床评估后24小时内使用吲哚菁绿血管造影(ICGA)评估ER。主要结局是1个月时的最佳矫正视力(BCVA)。
总共纳入70例患者,其中63例(90%)为CRAO。中位年龄为71岁(四分位间距:67 - 77岁),63%为男性,从症状发作到就诊的中位时间为5.3小时(四分位间距:3.1 - 15.1小时),17%接受了静脉溶栓治疗。34例患者(49%)出现ER,其中21例(30%)实现完全再灌注(55°ICGA视野100%充盈)。出现ER的患者患高血压和糖尿病的可能性较小(分别为<0.001和=0.046)。在1个月随访时,ER患者的BCVA明显更好(中位BCVA 1.3 logMAR对1.7 logMAR,=0.001),完全再灌注的获益更大(趋势检验<0.001)。ER还与1个月随访时视野和生活质量的改善相关(均<0.05)。
近50%的患者出现ER,且与视力预后和生活质量改善相关。增加CRAO中ER的治疗可能会改善临床结局。
本研究在ClinicalTrials.gov上注册(标识符);https://classic.clinicaltrials.gov/ct2/show/NCT03049514 。